Asset Details
Do you wish to reserve the book?
Eribulin in soft-tissue sarcoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Eribulin in soft-tissue sarcoma
Do you wish to request the book?
Eribulin in soft-tissue sarcoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Eribulin in soft-tissue sarcoma
2016
Overview
Sarcomas are unusual tumours that can occur at any anatomical site. Although they account for less than 1% of malignant tumours, they can be divided into more than 50 clinically and biologically distinct subtypes. Until recently, all soft-tissue sarcomas were treated the same way, but in the past decade, progress has been made in identifying clinical, histological, and molecular features to guide management. In a randomised open-label phase 3 trial in The Lancet, Patrick Schöffski and colleagues 2 report that eribulin improves overall survival in patients with advanced leiomyosarcoma and liposarcoma. Their report raises several interesting questions.
Publisher
Elsevier Ltd,Elsevier Limited
